| Hepsera 
              (Adefovir Dipivoxil)   Articles on Hepsera 
  Prescribing 
              Information   
  What 
              are Hepsera's Possible Side Effects? 
  Important 
              Safety Information about Hepsera 
  Is 
              There Resistance to Hepsera? 
 
  Articles on Hepsera (Adefovir Dipivoxil) 
 Entecavir 
              Beats Adefovir for Hepatitis 
              B Treatment
 3-29-2011
 
 Add-on 
               Hepsera Is More Effective and 
              Durable Than a Switch to Baraclude as Rescue Therapy for Epivir-resistant 
              Patients with Chronic Hepatitis B
 11-09-2010
 
 Adding 
               Adefovir Works Better than 
              Entecavir Monotherapy for Lamivudine-resistant Hepatitis B Patients
 8-27-2010
 
 Tenofovir 
              (Viread) Effective for Treatment of Chronic Hepatitis B Patients 
              with Suboptimal Response to Adefovir (Hepsera)
 5-7-2010
 
 Entecavir (Baraclude) Works Well 
              in Patients with Adefovir-resistant 
              Hepatitis B, but Lamivudine Resistance Compromises Efficacy
 4/02/2010
 
 Adding 
               Adefovir (Hepsera) to Lamivudine 
              (Epivir-HBV) Extends Biochemical Response, But May Cause Kidney 
              Problems
 3/19/2010
 
 Efficacy 
              and Safety of Entecavir Versus 
              Adefovir in Chronic Hepatitis B Patients with Evidence 
              of Hepatic Decompensation
 11/03/09
 
 Tenofovir 
              Disoproxil Fumarate for patients with chronic hepatitis B who have 
              previously failed Lamivudine and 
              Adefovir: effects of baseline sequence mutations on virological 
              response.
 11/03/09
 
 Entecavir (Baraclude) 
              Demonstrates Greater Antiviral Activity than Adefovir 
              (Hepsera) in Hepatitis B Patients with Decompensated 
              Liver Disease
 11/03/09
 
 Entecavir (ETV) Therapy in Chronic Hepatitis 
              B Patients Previously Treated with Adefovir 
              (ADV) with Incomplete Response On-Treatment or Relapse 
              Off-Treatment
 6/05/09
 
 Half 
              of HBeAg Negative Chronic Hepatitis B Patients Maintain Response 
              up to 5 Years after Stopping Long-term Adefovir (Hepsera)
 5/05/09
 
 Chronic 
              Hepatitis B Patients Who Had Incomplete Response or Relapse on Adefovir 
              (Hepsera) Respond Well to Entecavir (Baraclude)
 5/01/09
 
 Some 
              Individuals Harbor HBV with Adefovir (Hepsera) and Tenofovir 
              (Viread) Resistance Mutations before They Ever Receive Treatment
 4/17/09
 
 Two Year Tenofovir Disoproxil Fumarate (TDF) Treatment 
              and Adefovir Dipivoxil (ADV) Switch 
              Data in HBeAg-Positive Patients With Chronic Hepatitis B (Study 
              103)
 3/27/09
 
 Adefovir 
              (Hepsera) Prevents Post-transplant HBV Recurrence as 
              well as HBIG
 1/27/2009
 
 Higher 
              Dose of Adefovir (Hepsera) Are 
              Not Effective for Chronic Hepatitis B Patients with Lamivudine (Epivir) 
              Resistance
 1/09/2009
 
 
 
 
  What 
              are Hepsera's Possible Side Effects? 
 Hepsera® 
              (adefovir dipivoxil) was compared to a sugar pill (placebo) in clinical 
              trials. The most common side effects observed were weakness, headache, 
              stomach pain and nausea.
 Hepsera also 
              can cause the following serious side effects (See Important Safety 
              Information): very serious hepatitis if you stop taking it, a severe 
              kidney problem called nephrotoxicity, lactic acidosis (buildup of 
              acid in the blood) and liver problems. The most common 
              side effects in patients with liver transplants and chronic hepatitis 
              B were weakness, headache, stomach pain and itching. Some patients 
              with liver transplants also had changes in the way their kidneys 
              worked. If you notice any side effects while taking Hepsera, talk 
              to your healthcare provider about what to do.
 
 
  Important 
              Safety Information 
 1. Some people who stop taking Hepsera get a very serious 
              hepatitis. This usually happens within 12 weeks after stopping. 
              You will need to have regular blood tests to check for liver function 
              and hepatitis B virus levels if you stop taking Hepsera.
 2. Hepsera 
              may cause a severe kidney problem called nephrotoxicity. It 
              usually happens in people that already have a kidney problem, but 
              it can happen to anyone that uses Hepsera. You will need to have 
              regular blood tests to check for kidney function while you are taking 
              Hepsera. 3. Some 
              people who have taken medicines like Hepsera that are called nucleoside 
              or nucleotide analogs have developed a serious condition called 
              lactic acidosis (build up of an acid in the blood). Lactic acidosis 
              is a medical emergency and must be treated in the hospital. Call 
              your doctor right away if you get any of the following signs of 
              lactic acidosis:   
               
                You feel 
                  very weak or tired. You have unusual (not normal) muscle pain.
 You have trouble breathing.
 You have stomach pain with nausea and vomiting.
 You feel cold, especially in your arms and legs.
 You feel dizzy or lightheaded.
 You have a fast or irregular heartbeat.
  
              Some people 
                who have taken medicines like Hepsera have developed serious liver 
                problems called hepatotoxicity, with liver enlargement (hepatomegaly) 
                and fat in the liver (steatosis). Call your doctor right away 
                if you get any of the following signs of liver problems.   
              Your 
                skin or the white part of your eyes turns yellow (jaundice). Your urine turns dark.
 Your bowel movements (stools) turn light in color.
 You don't feel like eating food for several days or longer.
 You feel sick to your stomach (nausea).
 You have lower stomach pain.
  
              You may be 
                more likely to get lactic acidosis or serious liver problems if 
                you are very overweight (obese) or have been taking nucleoside 
                analog medicines [Atripla (efavirenz plus emtricitabine 
                plus tenofovir disoproxil fumarate), Combivir® (zidovudine 
                plus lamivudine), Emtriva® (emtricitabine), Epivir® Epivir-HBV® 
                (lamivudine), Epzicom (abacavir plus lamivudine), Hivid® 
                (zalcitabine), Retrovir® (zidovudine), Trizivir® (zidovudine 
                plus lamivudine plus abacavir), Truvada® (emtricitabine plus 
                tenofovir disoproxil), Videx® (didanosine), Viread® (tenofovir 
                disoproxil fumarate), Zerit® (stavudine) and Ziagen® (abacavir)] 
                for a long time.   
              4. 
                If you get or have HIV that isn't being treated with medicines, 
                Hepsera may increase the chances your HIV infection cannot be 
                helped with usual HIV medicines. This can happen if you get 
                or have HIV and don't know it, or if your HIV is not being treated 
                while you are taking Hepsera. You should get an HIV test before 
                you start taking Hepsera and any time after that when there's 
                a chance you were exposed to HIV.  
 
  Is 
                There Resistance to Hepsera?
  Drug resistance 
                is a primary concern of infectious disease specialists around 
                the world. Any virus can develop drug resistance, and may even 
                develop resistance to more than one drug. Resistance occurs when 
                viruses acquire ways to survive the effects of the drugs that 
                were designed to weaken them. Resistance to antiviral drugs presents 
                an obstacle to providing effective long-term treatment of viral 
                diseases, such as chronic hepatitis B. Hepsera® 
                was studied in clinical trials to find out whether or not resistance 
                would develop. Through 144 weeks (about 3 years), resistance mutations 
                were identified that may reduce the effectiveness of Hepsera. 
                After 3 years of continuous treatment, 4/100 patients developed 
                resistance to Hepsera in clinical trials. In clinical 
                trials, Hepsera was found to work well in people who had hepatitis 
                B virus that was resistant to the currently approved chronic hepatitis 
                B treatment, lamivudine.                   
 
                         
                                                 
 |